Detection of carbapenemase and blaOXA-23-like gene in carbapenem-resistant Acinetobacter baumannii at Sunpasitthiprasong Hospital
Article Sidebar
Main Article Content
Abstract
Introduction: Acinetobacter baumannii is a gram negative bacterium causing nosocomial infection resulting in a high prevalence of antibiotic resistances. An increase in the prevalence of carbapenem-resistant A. baumannii (CRAB) has been reported worldwide. The objectives of this study were to investigate the antimicrobial resistance rates in clinical isolates of A. baumannii isolated from in-patients at Sunpasitthiprasong Hospital and to examine the occurrence of OXA-23 like carbapenemase among the CRAB isolates. Materials and Methods: The antimicrobial susceptibility of 33 A. baumannii clinical isolates was tested by agar disk diffusion. Fourteen isolates of CRAB were selected and subjected in detection of carbapenemase production by modified Hodge test. The occurrence of blaOXA-23-like gene in CRAB isolates was detected by polymerase chain reaction (PCR). The amplified fragment was purified and subjected to DNA sequencing. Results: Sixteen of thirty-three A. baumannii isolates (48.5%) were carbapenem resistance. Imipenem and meropenem resistance rates were 45.2% and 61.5%, respectively. Carbapenemase-producing isolates revealed by modified Hodge test was 71.4% (10 of 14). Out of 14 CRAB isolates, the blaOXA-23-like gene was detected in the majority (85.7%). Conclusion: This study reported data on antimicrobial resistance rate of clinical isolates of A. baumannii isolated at Sunpasitthiprasong Hospital. A. baumannii showed a high rate of antimicrobial resistance to commonly used antibiotics. In addition, the occurrence of OXA-23 like carbapenemase-producing strains among CRAB isolates was demonstrated.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Afzal-Shah M, Livermore DM. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998; 41: 576-577.
Aimsaad L, Diraphat P, Utrarachkij F, Thunyaharn S, Samakoses R, Siripanichgon K. Epidemiological characteristics of Acinetobacter baumannii infections at Phramongkutklao Hospital. J Med Assoc Thai 2009; 92(Suppl. 7): S164-172.
Amudhan SM, Sekar U, Arunagiri K, Sekar B. OXA beta-lactamase-mediated carbapenem resistance in Acinetobacter baumannii. Indian J Med Microbiol 2011; 29: 269-274.
Bergogne-Bérézin E and Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9(2): 148–165.
Chaiwarith R, Mahatthanaphak S, Boonchoo M, Supparatpinyo K, Sirisanthana T. Pandrug-resistant Acinetobacter baumannii at Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents 2005; 22: 1-8.
Chen C-M, Liu P-Y, Ke S-C, Wu H-J, Wu L-T. Investigation of carbapenem-resistant Acinetobacter baumannii isolates in a district hospital in Taiwan. Diagn Microbiol Infect Dis 2009; 63: 394-397.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 18th informational supplement. CLSI M100-S18. Wayne, PA. Clinical and Laboratory Standards Institute 2008.
Dejsirilert S, Tiengrim S, Sawanpanyalert P, Aswapokee N, Malathum K. Antimicrobial resistance of Acinetobacter baumannii: six years of National Antimicrobial Resistance Surveillance Thailand (NARST) Surveillance. J Med Assoc Thai 2009; 92(Suppl. 4): S34-45.
Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010; 35: 219-226.
Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: 692-699.
Hall GS. Nonfermenting and miscellaneous gram-negative bacilli. In: Mahon CR, Lehman DC, Manuselis G, editors. Textbook of diagnostic microbiology. 3rd ed. St. Louis: Saunders-Elsevier; 2007. 567, 570.
Hujer KM, Hujer AM, Hulten EA, et al. Analysis of Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50(12): 4114–4123.
Karageorgopoulos DE, Kelesidis T, Kelesidis I and Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62 (1): 45-55.
Keerasuntonpong A, Samakeenich C, Tribuddharat C, Thamilkitkul V. Epidemiology of Acinetobacter baumannii infections in Siriraj Hospital 2002. Siriraj Med J 2006; 58: 951-954.
Kulah C, Mooij MJ, Comert F, et al. Characterisation of carbapenem-resistant Acinetobacter baumannii outbreak strains producing OXA-58 in Turkey. Int J Antimicrob Agents 2010; 36(2): 114-118.
Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-ß-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001; 7: 88-91.
Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254–1263.
Miller JM, Holmes HT, Krisher K. General principles of specimen collection and handling.
In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (eds). Manual of Clinical Microbiology. 8th ed. Washington, DC. : American Society for Microbiology; 2003: 55-66.
Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010; 16(1): 35-40.
Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358: 1271-1281. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents 2011; 37(2): 102-109.
Niumsup PR, Boonkerd N, Tansawai U, Tiloklurs M. Carbapenem-resistant Acinetobacter baumannii producing OXA-23 in Thailand. Jpn J Infect Dis 2009; 62: 152-154.
Opazo A, Domínguez M, Bello H, Amyes SGB, González-Rocha G. OXA-type carbapenemases in Acinetobacter baumannii in South America. J Infect Dev Ctries 2012; 6(4):311-316.
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Rev 2008; 21(3): 538–582.
Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12(9): 826-836.
Routsi C, Pratikaki M, Platsouka E, et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010; 38: 173-180.
Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of clinical microbiology. 8th ed. Washington, DC: ASM Press; 2003. 750-753.
Sunpasitthiprasong Hospital, Clinical Pathology Department. Annual report of antimicrobial susceptibility. Ubon Ratchathani: Sunpasitthiprasong Hospital; 2006.
Thapa B, Tribuddharat C, Srifuengfung S, Dhiraputra C. High prevalence of BLAOXA-23 in oligoclonal carbapenem-resistant Acinetobacter baumannii from Siriraj hospital, Mahidol university, Bangkok, Thailand. Southeast Asian J Trop Med Public Health 2010; 41: 625-635.
Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries 2009; 3: 335-341.